These substances are related to the DEA’s interest in researching hallucinogenic controlled products for clinical tests and research. The DEA asserts that it wants to support the regulated trials of schedule 1 substances, so increasing the production quota explains why this move is essential. The DEA also wants to research the requirements for manufacturing new drugs and the kind of impact marijuana has on the body. These steps are taken to work towards the Food and Drug Administration’s possibilities to approve a new drug.
Candies, Z, OGs, and more from Leafly’s senior editor. The post David Downs’ sickest weed…
According to a recent study published in the British Food Journal, roughly 53-56% of beer…
It’s news surrounding the results of a controversial study, claiming that cannabis use can cause…
In a significant development within the cannabis industry, Adam Levin, the chairman of Hightimes Holding…
Sheep counters everywhere can get excited about a new product from the effects-obsessive folks at…
So, I did what any reasonable cannabis enthusiast would do when confronted with the impending…